Kunming, China, June 02, 2023
KBI has a large colony of obese NHP models readily available for the needs of research services.
We routinely evaluate anti-obese efficacy with a wide range of tools including the following techniques:
· measurements of caloric intake and body mass index (BMI)
· quantification of body fat composition with dual energy X-ray absorptiometry (DEXA and iDXA)
· measurement of ectopic fat accumulation with magnetic resonance imaging (MRI)
· molecular biomarkers (such as adipokine mRNA expression) from fat biopsy in the area of interest

Further, we have successfully provided successful services for the evaluation of anti-obese drugs with associated diseases at different stages including:
· dyslipidemia (including triglyceride, cholesterol, LDL-C, HDL-C and lipoproteins)
· pre-diabetes, diabetes and diabetic complications (such as diabetic chronic kidney disease)
· non-alcoholic fatty liver disease
· cardiovascular disease (such as hypertension and heart failure)
Contact us if you need more information.